DETAILED ACTION
Claims 1, 7, 9-12, 16, 21-29, 32, 36, 54-63 are pending in the instant application.
Applicant’s election of (I), claims 1, 7, 9-12, 16, 21-29, 32, 36 in the reply filed on 07/13/2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)).
The requirement is still deemed proper and is therefore made FINAL.
Claims 1,7,9-12,16,21-29,32,36 are examined. Claims 54-63 are withdrawn per 37 CFR 1.142(b).
2. Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claims 1,7,9-12,16,21, 23, 25, 27-29,32,36 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Palfreyman et al., US 20240366655. Palfreyman et al. discloses the instant claimed compound, which from the STN search is
PNG
media_image1.png
250
406
media_image1.png
Greyscale
, which anticipates the instant compounds. Therefore, the instant claims are anticipated by Palfreyman et al.
Claims 1,7,9-12,16,21, 23, 25, 27-29,32,36 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Slassi et al., US 20240166599. Slassi et al. discloses the instant claimed compound, which from the STN search is
PNG
media_image2.png
514
522
media_image2.png
Greyscale
, which anticipates the instant compounds. Therefore, the instant claims are anticipated by Slassi et al.
Claims 1,7,9-12,16,21, 23, 25, 27-29,32,36 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Rands et al., US 11773062. Rands et al. discloses the instant claimed compound, which from the STN search is
PNG
media_image3.png
240
436
media_image3.png
Greyscale
, which anticipates the instant compounds. Therefore, the instant claims are anticipated by Rands et al.
Claims 1,7,9-12,16,21, 23, 25, 27-29,32,36 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Nivorozhkin et al., US 11242318. Nivorozhkin et al. discloses the instant claimed compound, which from the STN search is
PNG
media_image4.png
306
526
media_image4.png
Greyscale
PNG
media_image5.png
458
588
media_image5.png
Greyscale
, which anticipates the instant compounds. Therefore, the instant claims are anticipated by Nivorozhkin et al.
Claims 1,7,9-12,16,21, 23, 25, 27-29,32,36 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Rands et al., US 12042564. Rands et al. discloses the instant claimed compound, which from the STN search is
PNG
media_image6.png
68
566
media_image6.png
Greyscale
PNG
media_image7.png
796
706
media_image7.png
Greyscale
, which anticipates the instant compounds. Therefore, the instant claims are anticipated by Rands et al.
Claims 1,7,9-12,16,21, 23, 25, 27-29,32,36 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Morris et al., Journal of Labelled Compounds and Radiopharmaceuticals (1993), 33(6), 455-65. Morris et al. discloses the instant claimed compound, which from the STN search is
PNG
media_image8.png
58
562
media_image8.png
Greyscale
PNG
media_image9.png
166
250
media_image9.png
Greyscale
, which anticipates the instant compounds. Therefore, the instant claims are anticipated by Morris et al.
Claims 1,7,9-12,16,21, 23, 25, 27-29,32,36 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Barker et al., Biochemical Pharmacology (1982), 31(15), 2513-16. Barker et al. discloses the instant claimed compound, which from the STN search is
PNG
media_image8.png
58
562
media_image8.png
Greyscale
PNG
media_image9.png
166
250
media_image9.png
Greyscale
, which anticipates the instant compounds. Therefore, the instant claims are anticipated by Barker et al.
Claims 1,7,9-12,16,21, 23, 25, 27-29,32,36 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Beaton et al., Pharmacology, Biochemistry and Behavior (1982), 1695), 811-14. Beaton et al. discloses the instant claimed compound, which from the STN search is
PNG
media_image8.png
58
562
media_image8.png
Greyscale
PNG
media_image9.png
166
250
media_image9.png
Greyscale
, which anticipates the instant compounds. Therefore, the instant claims are anticipated by Beaton et al.
Claim Objections
Claims 22, 24, 26 are objected to as being dependent upon a rejected base claim 1, but would be allowable if rewritten in independent form including all of the limitations of the base claims and any intervening claims.
11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Niloofar Rahmani whose telephone number is
571-272-4329. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor, can be reached on 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
/NILOOFAR RAHMANI/
07/27/2026
Prosecution Insights